Efforts to improve response rates now focus on rational combinations: ICB plus chemotherapy, anti-TGF-β agents, CSF1R inhibitors (targeting TAMs), or intravesical agents that modulate the tumor immune microenvironment (51). Here, TGFB1 is linked to neoplasm.